AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 277 filers reported holding AMICUS THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $8,860,810 | -0.6% | 728,685 | +2.7% | 0.26% | +9.1% |
Q2 2023 | $8,913,468 | +0.9% | 709,671 | -10.9% | 0.24% | -5.1% |
Q1 2023 | $8,833,895 | +102691.4% | 796,564 | +13.2% | 0.26% | -5.6% |
Q4 2022 | $8,594 | -99.9% | 703,867 | -13.4% | 0.27% | -1.8% |
Q3 2022 | $8,481,000 | +1.2% | 812,361 | +4.1% | 0.28% | +8.7% |
Q2 2022 | $8,382,000 | +7.0% | 780,404 | -5.7% | 0.25% | +36.0% |
Q1 2022 | $7,835,000 | -22.5% | 827,320 | -5.4% | 0.19% | -7.9% |
Q4 2021 | $10,104,000 | +49.0% | 874,771 | +23.2% | 0.20% | +43.3% |
Q3 2021 | $6,779,000 | -2.4% | 709,852 | -1.5% | 0.14% | +12.8% |
Q2 2021 | $6,946,000 | +1.9% | 720,586 | +4.5% | 0.12% | -0.8% |
Q1 2021 | $6,815,000 | -56.0% | 689,787 | +2.8% | 0.13% | -57.1% |
Q4 2020 | $15,489,000 | +11.6% | 670,818 | -31.8% | 0.29% | -20.1% |
Q3 2020 | $13,884,000 | -6.7% | 983,297 | -0.3% | 0.37% | -13.0% |
Q2 2020 | $14,875,000 | +27.8% | 986,416 | -21.7% | 0.42% | +1.4% |
Q1 2020 | $11,643,000 | -4.8% | 1,260,107 | +0.4% | 0.42% | +34.1% |
Q4 2019 | $12,229,000 | – | 1,255,580 | – | 0.31% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |